Aethlon Medical, Inc. (NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Oncology Stock News Bite - G1 Therapeutics (NASDAQ: GTHX) Trades Up on Fourth Quarter and Full Year 2023 Financial Results
Biopharma Stock News Bite - Janux Therapeutics, Inc. (Nasdaq: JANX) Spikes over 200% on News Making it Nasdaq's Top Gainer
Biotech Stock News Bite - Krystal Biotech (NASDAQ: KRYS) Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Biotech Stock News Bite - Immunic, Inc. (Nasdaq: IMUX) Year End 2023 Financial Results and Provides Corporate Update
Biotech Stock News Bite - Ventyx Biosciences, Inc. (NASDAQ: VTYX) Makes Top Gainer List on NASDAQ
Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
Focus on Biotech and AI Stocks: (Nasdaq: IMTX) (Nasdaq: MDAI) (NASDAQ: BFRG) (CSE: INVR)
Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData
Focus on Biotech Stocks: (NASDAQ: CRDL) (NASDAQ: KA) (TSXV: MDCX) (OTCQB: SKYE)
Life Sciences Stock News Bite - Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.
iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.
iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.
iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.
iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.
Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund&#39;s benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
The Rise of Mobile Applications in Healthcare and Medicine - September 5, 2023
How to Prove Wrongful Death - February 1, 2022
Healthcare Supply Chain Management Software - November 29, 2021
Overview of Biotech Stocks - What Could Happen by the End of 2021? - November 3, 2021
Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021
Resources for Physicians and Medical Practices - December 31, 2020
Lockdown Part 2: The South African Economy and the Rand - December 15, 2020
How to Get Into Canada during COVID - November 30, 2020
Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020
Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020
The Rise Of The At-Home Testing Market - January 16, 2020
Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019
Cell MedX Corp. Announces Resignation of Director
PlantFuel Advances Its Innovative Product Portfolio with Amplify Nutrition Pre-Workout and Electrolyte Gummies
BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities
ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman